Portal de Periódicos da CAPES

Is a new COVID‐19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data

2023; Wiley; Volume: 95; Issue: 3 Linguagem: Inglês

10.1002/jmv.28601

1096-9071

Francesco Branda, Fabio Scarpa, Massimo Ciccozzi, Antonello Maruotti,

COVID-19 Clinical Research Studies

Journal of Medical VirologyVolume 95, Issue 3 e28601 LETTER TO THE EDITOR Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data Francesco Branda, Francesco Branda orcid.org/0000-0002-9485-3877 Department of Computer Science, Modeling, Electronics and Systems Engineering (DIMES), University of Calabria, Rende, ItalySearch for more papers by this authorFabio Scarpa, Fabio Scarpa orcid.org/0000-0002-3501-714X Department of Biomedical Sciences, University of Sassari, Sassari, ItalySearch for more papers by this authorMassimo Ciccozzi, Massimo Ciccozzi orcid.org/0000-0003-3866-9239 Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, ItalySearch for more papers by this authorAntonello Maruotti, Corresponding Author Antonello Maruotti [email protected] orcid.org/0000-0001-8377-9950 Department GEPLI, Libera Università Maria Ss Assunta, Rome, Italy Correspondence Antonello Maruotti, Department GEPLI, Libera Università Maria Ss Assunta, Rome, Italy. Email: [email protected]Search for more papers by this author Francesco Branda, Francesco Branda orcid.org/0000-0002-9485-3877 Department of Computer Science, Modeling, Electronics and Systems Engineering (DIMES), University of Calabria, Rende, ItalySearch for more papers by this authorFabio Scarpa, Fabio Scarpa orcid.org/0000-0002-3501-714X Department of Biomedical Sciences, University of Sassari, Sassari, ItalySearch for more papers by this authorMassimo Ciccozzi, Massimo Ciccozzi orcid.org/0000-0003-3866-9239 Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, ItalySearch for more papers by this authorAntonello Maruotti, Corresponding Author Antonello Maruotti [email protected] orcid.org/0000-0001-8377-9950 Department GEPLI, Libera Università Maria Ss Assunta, Rome, Italy Correspondence Antonello Maruotti, Department GEPLI, Libera Università Maria Ss Assunta, Rome, Italy. Email: [email protected]Search for more papers by this author First published: 23 February 2023 https://doi.org/10.1002/jmv.28601Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Iftekhar EN, Priesemann V, Balling R, et al. A look into the future of the COVID-19 pandemic in Europe: an expert consultation. Lancet Reg Health Eur. 2021; 8:100185. 2Maruotti A, Giovanetti M, Divino F, Broccolo F, Angeletti S, Ciccozzi M. Prisoners of variants, or free to act as prisoners of swabs? The case of Italy. J Med Virol. 2022; 94(6): 2334-2335. 3Ciccozzi M, Maruotti A, Ceccarelli G, Divino F, Guarino M, Angeletti S. While we are discussing the SARS-CoV-2 virus laughs. J Med Virol. 2021; 93(12): 6475-6476. 4Krueger T, Gogolewski K, Bodych M, et al. Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes. Commun Med. 2022; 2(1): 23. 5Branda F, Abenavoli L, Pierini M, Mazzoli S. Predicting the spread of SARS-CoV-2 in Italian regions: the calabria case study, February 2020-March 2022. Diseases. 2022; 10(3): 38. 6Alaimo Di Loro P, Divino F, Farcomeni A, et al. Nowcasting COVID-19 incidence indicators during the Italian first outbreak. Stat Med. 2021; 40(16): 3843-3864. 7Francesconi M, Giovanetti M, De Florio L, et al. Genomic epidemiology unveil the omicron transmission dynamics in Rome, Italy. Pathogens. 2022; 11(9): 1011. 8Scarpa F, Sanna D, Benvenuto D, et al. Genetic and structural data on the SARS-CoV-2 Omicron BQ. 1 variant reveal its low potential for epidemiological expansion. Int J Mol Sci. 2022; 23(23):15264. 9Mallapaty S. China's COVID vaccines have been crucial—now immunity is waning. Nature. 2021; 598(7881): 398-399. 10Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA. 1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. Euro Surveill. 2022; 27(6):2200042. 11Mefsin YM, Chen D, Bond HS, et al. Epidemiology of infections with SARS-CoV-2 omicron BA.2 variant, Hong Kong, January-March 2022. Emerging Infect Dis. 2022; 28(9): 1856-1858. 12Xin H, Wang Z, Feng S, et al. Transmission dynamics of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022. Int J Infect Dis. 2023; 126: 132-135. 13Acosta N, Bautista MA, Waddell BJ, et al. Surveillance for SARS-CoV-2 and its variants in wastewater of tertiary care hospitals correlates with increasing case burden and outbreaks. J Med Virol. 2023; 95:e28442. 14Scarpa F, Sanna D, Azzena I, et al. Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages. bioRxiv; 2022. doi:10.1101/2022.12.20.521197 15Scarpa F, Sanna D, Azzena I, et al. On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view. J Med Virol. 2023; 95:e28119. 16Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022; 602(7898): 676-681. 17Le Targa L, Wurtz N, Lacoste A, et al. SARS-CoV-2 testing of aircraft wastewater shows that mandatory tests and vaccination pass before boarding did not prevent massive importation of omicron variant into Europe. Viruses. 2022; 14(7): 1511. 18Tiseo G, Yahav D, Paul M, et al. What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. Eur J Clin Microbiol Infect Dis. 2022; 41(2): 281-288. 19Falcone M, Tiseo G, Valoriani B, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther. 2021; 10(4): 2479-2488. 20Tiseo G, Barbieri C, Galfo V, et al. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience. Infect Dis Ther. 2022; 1-15: 9-2488. 21Falcone M, Suardi LR, Tiseo G, et al. Early use of remdesivir and risk of disease progression in hospitalized patients with mild to moderate COVID-19. Clin Ther. 2022; 44(3): 364-373. Citing Literature Volume95, Issue3March 2023e28601 This article also appears in:Monkeypox Virus and Related Poxviruses - Part II ReferencesRelatedInformation